The invasive nature of cancers in general, and malignant gliomas in particular, is a major clinical problem rendering tumors incurable by conventional therapies. Using a novel invasive glioma mouse model established by serial in vivo selection, we identified the p75 neurotrophin receptor (p75NTR) as a critical regulator of glioma invasion. Through a series of functional, biochemical, and clinical studies, we found that p75NTR dramatically enhanced migration and invasion of genetically distinct glioma and frequently exhibited robust expression in highly invasive glioblastoma patient specimens. Moreover, we found that p75NTR-mediated invasion was neurotrophin dependent, resulting in the activation of downstream pathways and producing striking cytoskeletal changes of the invading cells. These results provide the first evidence for p75NTR as a major contributor to the highly invasive nature of malignant gliomas and identify a novel therapeutic target.
Gliomas are highly malignant and invasive tumors with tendrils that extend far from the primary tumor site, rendering conventional therapies ineffective and leading to an invariably poor prognosis. To understand the molecular mechanisms underlying this invasive behavior, we injected immunocompromised mice with human gliomas and compared invasive cells, which left the primary tumor site, to noninvasive cells, which remained at the site of injection. We identified the neurotrophin receptor p75NTR—which normally functions during development to induce neurite outgrowth and promote neuronal cell death—as an important regulator of glioma invasion. We present the first evidence that this neurotrophin receptor can also be a potent mediator of glioma invasion, and we show that the expression of this receptor is sufficient to impart a dramatic invasive behavior on genetically distinct tumors. These data highlight a previously unknown function of this receptor and suggest it may be a novel therapeutic target in the treatment of this devastating cancer.
Citation: Johnston ALM, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, et al. (2007) The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. PLoS Biol 5(8): e212. doi:10.1371/journal.pbio.0050212
Academic Editor: Christopher Kemp, Fred Hutchinson Cancer Research Center, United States of America
Received: December 20, 2006; Accepted: June 8, 2007; Published: August 14, 2007
Copyright: © 2007 Johnston et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by a generous donation from the Clark H. Smith Family, and by grants from the Cancer Research Society (SMR and PAF) and the Canadian Institute of Health Research (PAF and DLS).The Southern Alberta Microarray Facility provided support and infrastructure for the DNA microarray experiments.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: ANOVA, analysis of variance; BDNF, brain-derived neurotrophic factor; CRD, cysteine-rich domain; ELISA, enzyme-linked immunosorbent assay; GBM, glioblastoma multiforme; GFP, green fluorescent protein; NGF, nerve growth factor; p75NTR, p75 neurotrophin receptor; pro-NGF, proform of NGF; RT-PCR, real-time polymerase chain reaction; SCID;, severe combined immunodeficiency; siRNA, small interfering ribonucleic acid; Trk, tropomysin receptor kinase
Malignant gliomas are diffuse, highly invasive, and often multifocal tumors that have a dismal prognosis, with a median survival of only 1 y and “long-term survivors” (i.e., surviving ≥3 y) are rare [1,2]. A major barrier to effective malignant glioma treatment is their highly invasive nature; they extend tendrils of tumor several centimeters away from the main tumor mass, which render these tumors incurable by local therapies such as surgery or radiotherapy . Ninety-five percent of gliomas recur within 2.5 cm of the resection margin, which contains invasive cells that act as a “disease reservoir” and elude current treatments . Glioma cells do this by becoming distinct from their noninvasive counterparts. Specifically, they activate a number of coordinate cellular programs, which include those necessary for migration (e.g., motility) and invasion (e.g., extracellular matrix degradation)  and also a number of pathways (e.g., reduced proliferation, marked resistance to apoptosis) [4,6,7] which render the invasive cells highly resistant to conventional treatments. A detailed understanding of the mechanisms underlying this invasive behavior is essential for the development of effective therapies.
Although in their infancy, attempts to identify genes involved in glioma invasion have used a number of techniques, including the isolation of invasive cells from human cell lines in vitro [6,7], the use of organotypic brain slice cultures , and the collection of tumor and invasive cells from frozen glioblastoma patient specimens using laser capture microdissection [9–11]. Although each method has been successful in its own right, none of these models have been ideal or comprehensive for discovering the underlying mechanisms of invasion. New models or alternative strategies are needed. We have therefore undertaken the approach of serial in vivo selection to identify genes important for the invasive behavior of malignant glioma. Similar strategies have been used to effectively identify mechanisms underlying the metastatic behavior of both melanoma and breast tumors [12,13]. Using this approach, we isolated highly invasive glioma cells from a relatively noninvasive human malignant glioma. Gene expression profiles comparing these two tumor cell populations identified the p75 neurotrophin receptor (p75NTR) as an important and potent mediator of invasion in human glioma.
p75NTR is a transmembrane glycoprotein and a member of the tumor necrosis factor (TNF) superfamily that was originally isolated as a nerve growth factor (NGF) receptor, but has since been shown to bind both the mature and precursor forms of the neurotrophin family of ligands (brain-derived neurotrophin factor [BDNF], neurotrophin-3 [NT-3], and neurotrophin-4/5 [NT-4/5]) [14–18]. In neurons, p75NTR is coexpressed with a second group of neurotrophin receptors, the tropomysin receptor kinases (Trks). It has become increasingly clear that the dogma in neuroscience that Trks mediate neuronal survival and p75NTR causes neuronal cell death is too narrow a view [19–22]. Rather, there is a growing appreciation that p75NTR, like other members in the TNF superfamily, mediates a very broad range of cellular functions, depending on the cell context and the repertoire of co-receptors that exist (e.g., Trks , Nogo receptor , and sortilin ). In neurons, p75NTR has been shown to increase [26,27] or inhibit  axon growth, reduce  or promote [30,31] neuronal cell death, and is either necessary  or not required  for inhibition of neuronal regeneration. These apparent discrepancies are not confined to neurons; p75NTR has also been shown to both inhibit  and promote [26,35] Schwann cell migration during development. Even though p75NTR does not contain any catalytic activity, it interacts with several proteins that help transmit signals required for its various functions. Neurotrophin engagement of p75NTR controls the activity of the small GTPase RhoA, providing a direct link from the receptor to modulating cellular architecture. As is the case for phenotypic responses, RhoA has been shown to be activated or inhibited depending on cellular context [27,28,34,36–38]. Reports have hinted at roles for p75NTR in growth  and apoptosis  of glioma cells; however, data presented here support a much different role for p75NTR—that of mediating glioma cell invasion.
Establishment of a Malignant Glioma Mouse Model to Study the Molecular Determinants of Glioma Invasion
One of the problems in xenotransplanting human glioma cells into the brains of immunocompromised mice is that the resulting tumors are circumscribed, with very little cell infiltration into the brain parenchyma . To generate an orthotopic model that more closely mimics the human disease and allows for the identification of molecular determinants of glioma invasion in a global and unbiased manner, we used an in vivo–selection procedure to select for highly invasive human glioma cells (Figure 1A). We isolated highly invasive glioma cells from the noninvasive human malignant glioma cell line U87 expressing green fluorescent protein (GFP) (U87GFP) and a neomycin resistance gene. Expression of these genes afforded us the ability to isolate the rare glioma cell that migrated away from the primary tumor site. These “invasive” cells were grown and expanded in tissue culture, and reintroduced into the brains of immunocompromised mice where they formed highly infiltrative tumors with poorly defined edges (Figure 1B). These extremely invasive cells were found vast distances from the main tumor mass, with GFP-positive tumor cells readily identifiable in the contralateral hemisphere. In clear contrast, reimplantation of the noninvasive “tumor” cells led to the formation of large tumors with sharply demarcated edges (Figure 1B). Using this model, we identified gene expression differences between the noninvasive and highly invasive in vivo–selected glioma cells. RNA extracted from tumor and invasive populations was used to prepare labeled cDNA that was hybridized to 14,000-gene human oligonucleotide microarrays (produced by the Southern Alberta Microarray Facility, University of Calgary). Genes up- or down-regulated in the invasive population were compared to the tumor population, and genes that showed consistent gene expression changes of 2-fold or greater are outlined in Figure 2A. To ensure the integrity of the microarray data, we chose seven arbitrary genes for validation, the expression of five of which are shown in Figure 2B and 2C. Semiquantitative real-time polymerase chain reaction (RT-PCR) confirmed the expression of all seven genes, including granulocyte colony-stimulating factor (G-CSF), interleukin-8 (IL-8), DZFKp434B204 (unknown hypothetical protein), tissue inhibitor of metalloproteinases-3 (TIMP-3), and p75NTR (Figure 2B and 2C). The semiquantitative RT-PCR indicates that our microarray data is an under-representation of the fold changes in RNA expression. Based on the reproducibility of the data, previous implication in tumorigenesis in other cancers (e.g., melanoma and prostate) [42–47], and the novelty of the finding in brain tumors, we chose p75NTR for further study. Importantly, we confirmed the up-regulation of p75NTR was not only at the mRNA level, but that a dramatic alteration in abundance of p75NTR was seen in the invading cells (Figure 2C). A number of invasive lines were generated by serial in vivo selection and microarray analysis using a second independent U87 invasive line validated the presence of p75NTR by microarray that was confirmed by RT-PCR and Western blot (unpublished data). In addition, using the in vivo–selection paradigm outlined in Figure 1, we isolated both tumor and invasive cells from a second human glioma cell line, U251N. These in vivo–selected invasive U251N cells also expressed high levels of endogenous p75NTR (Figure S1).
(A) The noninvasive human glioma cell line U87 stably expressing GFP (U87GFP) was implanted into the brains of SCID mice. Four to 6 wk later, the mice were sacrificed. The ipsilateral side of the brain (containing a grossly visible tumor) was separated from the contralateral side (containing only isolated invasive glioma cells [i.e., no macroscopically visible GFP-labeled tumor]), and both were grown in culture. These noninvasive (tumor) and highly invasive glioma cells were reimplanted into additional mice, and the process was repeated to select for increasingly noninvasive or invasive glioma cells. RNA extracted from the resulting invasive and tumor populations was used to prepare labeled cDNA that was hybridized to oligonucleotide microarrays.
(B) Brains of SCID mice implanted with either tumor (left) or invasive (center and right) glioma cells. GFP visualization reveal the well-circumscribed border of the reimplanted tumor cells, with no tumor cells being detected away from the main tumor mass (left). This is in sharp contrast to the highly invasive border of the invasive tumors, where isolated small groups of glioma cells are found throughout the brain (center and right). Scale bars on GFP images represent 125 μm (center) and 62 μm (right and left).
(A) Table lists results from a representative set of lineage experiments. Four independent microarray experiments were performed, each containing a pair of dye-flipped hybridizations. Genes that displayed consistent gene expression changes (>2-fold change in at least five out of eight hybridizations) are listed. The indicated ratios represent the fold change in gene expression in the invasive compared to the noninvasive cells. Genes chosen for validation are indicated in red.
(B and C) Seven genes were chosen for validation; the expression of five are shown. (B) RT-PCR confirmed the expression of granulocyte colony-stimulating factor (G-CSF), interleukin-8 (IL-8), an unknown hypothetical protein DZFKp434B204 (DZFK), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in the invasive population. Expression levels of GAPDH (unchanged) are shown for comparison. (C) RT-PCR and Western blot confirm expression of p75 in the invasive population (Inv) but not the tumor cell population (T). RT-PCR analysis of GAPDH levels and Western blot analysis of pyruvate kinase levels are included as loading controls. Human dorsal root ganglia (DRG) were used as a positive control.
(D) Addition of NGF (200 ng/ml) enhanced the migratory ability of the invasive glioma cells in matrigel-coated invasion chambers, but had no significant effect on invasion of the tumor cells. Values shown are the mean ± SEM from three independent experiments. Triple asterisks (***) indicate p < 0.001 versus control (two-way ANOVA with Bonferroni post-tests).
In Vivo Selection Identifies p75NTR as a Mediator of Glioma Invasion
Although p75NTR and its ligands, the neurotrophins, are expressed throughout the nervous system, particularly during development, a role for p75NTR in central nervous system tumors has not been described previously. We therefore assessed whether the up-regulation of p75NTR found in the invasive glioma cells had a functional consequence (i.e., increased their migration and invasion). The noninvasive and highly invasive cells were treated with the p75NTR ligand NGF, and migration and invasion were measured. The addition of NGF to invasive cells significantly increased the number of cells able to invade through matrigel, but had no effect on the invasive ability of the tumor cells (which had no detectable p75NTR; Figure 2D). Because neurotrophins are also ligands for the Trk receptors, RT-PCR and immunoprecipitation experiments were performed. No detectable mRNA or protein for the Trk receptors was found in the invading glioma cells (unpublished data). In addition, we tested the effect of the unprocessed or proform of NGF (pro-NGF), a high-affinity ligand for p75NTR [33,39] that is unable to activate Trk . Accordingly, treatment of the invasive cells with cleavage-resistant pro-NGF enhanced their migration at concentrations as low as 1 ng/ml while having no effect on the tumor cells (Figure S2). Although we found that neurotrophin could enhance invasion of the p75NTR-positive invasive cells (Figure 2D), we also observed a significant increase in the absence of ligand. Signals from p75NTR can arise both in the absence and presence of ligand; however, these signals often evoke opposing biological responses. Because the outcome of both neurotrophin-dependent and neurotrophin-independent signaling was the same, we considered the possibility that the glioma cells were producing and secreting neurotrophin(s), thus activating an autocrine loop. We assessed the expression of several neurotrophins and found that BDNF was present in both the conditioned media and the cell lysate of all glioma cells tested (unpublished data). Furthermore, we found that the presence of p75NTR shifted the localization of BDNF from the conditioned media to the cell membrane (Figure S3), supporting the notion of autocrine/paracrine activation of the p75NTR receptor.
To directly test the hypothesis that elevated expression of p75NTR is necessary for neurotrophin-induced glioma migration and invasion, we surveyed a panel of human glioma cell lines for p75NTR protein expression. We found that the human glioma cell line SF767 endogenously expressed high levels of p75NTR, as detected by Western blot (Figure 3A) and fluorescence-activated cell-sorting (FACS) analysis (unpublished data). Using RNA interference (RNAi), we down-regulated p75NTR in the SF767 cell line using an expression vector containing a p75NTR-specific small interfering ribonucleic acid (siRNA) and confirmed the down-regulation by RT-PCR and Western blot (Figure 3A). A random, nonspecific siRNA sequence was used as a control. Down-regulation of p75NTR levels in SF767 was sufficient to reduce its migration in vitro and rendered the cells nonresponsive to addition of NGF in both migration and invasion assays (Figure 3B and 3C). Similarly, down-regulation of p75NTR by siRNA in the original in vivo–selected U87 invasive cells significantly blocked migration and invasion (Figure S4).
(A) Down-regulation of p75NTR using RNAi decreases glioma migration/invasion. RT-PCR (GAPDH used as a loading control) and Western blot (pyruvate kinase used as a loading control) for p75NTR confirm down-regulation of p75NTR in the glioma cell line SF767 transfected with a p75-specific siRNA. Untransfected cells, cells transfected with a random siRNA, and the in vivo–selected tumor and invasive cells are shown for comparison.
(B) Treatment with NGF (200 ng/ml) enhanced migration of SF767 cells transfected with the random (control) siRNA, but had no significant effect on migration of SF767 cells in which p75NTR expression was inhibited by p75NTR-specific siRNA. Values shown are the mean ± SEM from three independent experiments. A single asterisk (*) indicates p < 0.05, and double asterisks (**) indicate p < 0.01 versus control-treated random siRNA-transfected cells; triple asterisks (***) indicate p < 0.001 versus NGF-treated random siRNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
(C) Treatment with NGF (200 ng/ml) enhanced invasion of SF767 cells transfected with random siRNA, but had no significant effect on invasion of SF767 cells in which p75NTR expression was inhibited by p75NTR-specific siRNA. Values shown are the mean ± SEM from a single experiment. Similar results were seen in two independent experiments. Double asterisks (**) indicate p < 0.01 versus control-treated random siRNA-transfected cells, and double pluses (++) indicate p < 0.01 versus NGF-treated random siRNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
(D) Ectopic expression of p75NTR induces glioma migration/invasion. RT-PCR (GAPDH used as a loading control) and Western blot (pyruvate kinase used as a loading control) for p75NTR confirm expression of p75NTR in U87 cells stably transfected with pcDNA3.1 encoding human p75NTR (U87p75). Cells stably transfected with the empty pcDNA3.1 vector (U87pcDNA), as well as in vivo–selected tumor and invasive cells are shown for comparison.
(E) Migration of U87 glioma cells is enhanced by ectopic expression of p75NTR. No additional increase was seen following treatment with NGF (200 ng/ml). Values shown are the mean ± SEM from three independent experiments. Triple asterisks (***) indicate p < 0.001 versus pcDNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
(F) Similarly, invasion of U87p75 glioma cells in matrigel-coated invasion chambers was significantly increased compared to controls. No further increase was seen with exogenous NGF (200 ng/ml). Values shown are the mean ± SEM from four independent experiments. A single asterisk (*) indicates p < 0.05, and double asterisks (**) indicate p < 0.01 versus pcDNA-transfected cells (two-way ANOVA with Bonferroni post-tests).
Since down-regulation of p75NTR in SF767 cells and U87 in vivo–selected invasive cells inhibited glioma invasion, we assessed whether ectopic expression of p75NTR alone was sufficient to increase glioma migration and invasion in a cell line without detectable p75NTR (the original U87 cell line). To this end, we stably transfected the full-length cDNA of human p75NTR into the U87 glioma cell line, using stable transfection of the empty pcDNA vector as a control. Expression levels of p75NTR in these cells were confirmed by RT-PCR and Western blot (Figure 3D). Expression of p75NTR caused a significant increase in migration and invasion in vitro (Figure 3E and 3F). Treatment of these cells with NGF had no further enhancement on their migration or invasion consistent with the idea that when p75NTR is expressed, an autocrine loop is completed, leading to enhanced migration and invasion.
Expression of p75NTR Increases Invasion In Vivo in Genetically Distinct Glioblastomas
Malignant gliomas clinically show extensive infiltration away from the main tumor and into the surrounding normal brain tissue. To determine whether the expression of p75NTR was important for glioma cell invasion in vivo, we implanted the U87 human glioma cell line ectopically expressing p75NTR into the brains of severe combined immunodeficiency (SCID) mice. U87 cells stably transfected with the empty pcDNA vector were implanted for comparison as a control. Twenty-eight days after implantation, the mice were sacrificed and the brains prepared for immunohistochemical staining using antibodies directed against human nuclei and p75NTR. Implantation of U87 glioma cells stably transfected with pcDNA led to the formation of well-circumscribed tumors that were p75NTR negative (Figure 4A). In sharp contrast, implantation of U87 glioma cells stably expressing p75NTR resulted in the formation of tumors with highly infiltrative edges (Figure 4B). Isolated p75NTR-positive human glioma cells could be detected in regions vastly distant from the main tumor mass (Figure S5).
U87 or U251N human glioma cells stably transfected with the empty pcDNA vector (U87pcDNA [A] or U251NpcDNA [C]) or the p75NTR-expression vector (U87p75 [B] or U251NpcDNA [D]) were implanted into the brains of SCID mice and allowed to grow for 28 d. The mice were sacrificed, and frozen brain sections were stained with antibodies against human nuclei (left) and human p75NTR (right). Boxed areas indicate the region shown in the panel below, thus magnification increases from top to bottom; scale bars in (A) and (B) represent 100 μm, 50 μm, and 25 μm; and scale bars in (C) and (D) represent 200 μm and 100 μm. Implantation of U87 glioma cells stably transfected with the empty pcDNA vector led to the formation of well-circumscribed tumors that were p75NTR negative (A). In sharp contrast, implantation of U87 glioma cells ectopically expressing p75NTR led to the formation of tumors with highly infiltrative edges (B). Similar results were seen in three independent experiments with six animals in each group. U251NpcDNA glioma cells were generally more invasive than U87pcDNA cells upon implantation into the brains of SCID mice, and formed tumors with finger-like projections extending into the surrounding normal brain (C); nevertheless, ectopic expression of p75NTR in U251N cells dramatically increased the invasiveness of these cells in vivo with isolated individual tumor cells being found distant from the main tumor mass (D). Similar results were seen in all ten animals in each group.
Because malignant gliomas are an extremely heterogeneous group of tumors and the in vivo–selected U251N cells also expressed high levels of p75 (Figure S1), we determined whether the sole expression of p75NTR was sufficient to impart an invasive phenotype, not only on the U87 cells, but also on the genetically distinct U251N cells. U251N cells ectopically expressing p75NTR (U251Np75), along with empty vector–transfected cells as a control (U251NpcDNA), were implanted into the brains of SCID mice as described above. As we have observed previously, the U251N control cell line (U251NpcDNA) was inherently more invasive than U87pcDNA in vivo, with finger-like projections extending from the main tumor mass into the surrounding normal brain (compare Figure 4A and 4C). Nevertheless, ectopic expression of p75NTR (U251Np75) dramatically enhanced the inherent invasive ability, with p75NTR-positive cells being found at locations distinct from the main tumor mass (compare Figure 4C and 4D). Thus, up-regulation of p75NTR is sufficient to allow glioma cells of diverse genetic backgrounds to invade into the surrounding normal brain. Because p75NTR can have effects on several physiological responses, we also evaluated the effect of p75NTR expression on cell cycle, proliferation, and survival, and observed no significant change (unpublished data).
p75NTR-Mediated Glioma Invasion Is Neurotrophin Dependent
In order to test whether neurotrophin was important in the invasive behavior of these cells, we constructed two p75NTR mutants, p75CRD105 and p75CRD130, containing a four–amino acid insertion in the cysteine-rich domain (CRD) following amino acids 105 and 130 (CRD 105 and CRD 130), respectively. Insertions at these locations disrupt the normal spacing of the cysteine residues within the164 ligand-binding domain and create p75NTR proteins that are unable to bind to mature neurotrophin . These constructs were stably transfected into U87 glioma cells, and cell surface expression for the mutant p75NTR proteins was confirmed by FACS analysis (Figure 5A). To verify that the mutant p75NTR do not bind neurotrophin, BDNF expression in the conditioned medium and total cell lysates of U87 cells expressing CRD105 and CRD130 were performed. Unlike the wild-type p75NTR-expressing glioma cells in which expression of p75NTR causes a shift in BDNF localization from the medium to the cell lysate, cells expressing the mutant alleles (CRD105 and CRD130) did not result in a shift of BDNF localization, confirming that these mutants do not bind endogenous BDNF (Figure 5B). These cells were implanted into the brains of SCID mice and allowed to grow for 21 d. The mice were sacrificed, and frozen brain sections were stained with antibodies against human nuclei (Figure 5C; brown color, top row) and human p75NTR (Figure 5C; brown color, bottom row). Disruption of the neurotrophin binding capacity of p75NTR results in tumors with well-defined borders similar to tumors formed by the parental U87 glioma cells that do not express p75NTR. These data suggest that neurotrophin binding is required for p75NTR-mediated glioma invasion.
(A) U87 human glioma cells stably transfected with wild-type p75NTR (red), the neurotrophin binding mutant p75CRD105 (green), and p75CRD130 (blue) or pcDNA empty vector (yellow) were examined for cell surface expression of p75 receptors by flow cytometry using the p75-specific primary antibody and an Alexa 448–conjugated secondary antibody.
(B) Expression of BDNF in the conditioned medium (blue bar) and the total cell lysate (yellow bar) of U87 glioma cells expressing pcDNA (control), p75NTR (p75), CRD 105, and CRD 130 were analyzed by ELISA. BDNF was found in the cell-associated fraction of U87 cells expressing p75, but not in the cells expressing the neurotrophin binding mutants CRD105 or CRD130.
(C) U87 cells expressing wild-type p75NTR, neurotrophin binding mutant CRD105, or CRD130 were implanted into the brains of SCID mice and allowed to grow for 28 d. The mice were sacrificed, and frozen brain sections were stained with antibodies against human nuclei (ANA; top row) and human p75NTR (bottom row). Scale bars in (C) represent 100 μm. Implantation of either U87 glioma cells stably transfected with CRD130 or CRD105 vector, in contrast to the highly infiltrative edges of U87p75, led to the formation of well-circumscribed tumors. Similar results were seen in three independent experiments with six animals in each group. Expression of neurotrophin binding mutants of p75NTR negates p75-induced glioma invasion.
p75NTR-Expressing Glioma Cells from Human Glioma Surgical Specimens Show Enhanced Migration
The highly invasive nature of malignant gliomas has been a substantial barrier in the treatment of patients with this disease. Data presented here strongly suggest that p75NTR, in a neurotrophin-dependent manner, is an important regulator of glioma invasion. To clinically validate p75NTR's role in glioma migration and invasion, and demonstrate its relevance in malignant glioma patient specimens, we analyzed the expression of p75NTR in a panel of surgically resected tumor specimens and normal human brain using immunohistochemical staining (Figure 6A), RT-PCR, and Western blot (Figure 6B). Expression of p75NTR protein was detected in 20 of 40 human glioma patient specimens (50%) (one of 11 low-grade astrocytomas [8%], two of nine mid-grade astrocytomas [22%], and 17 of 20 glioblastoma multiforme (GBM) specimens [85%]) and was undetectable in normal human brain (zero of five). Thus, expression of p75NTR is a common event in GBM. To demonstrate that the presence of p75NTR in these patient specimens confers an increased migratory ability, short-term cultures of these samples were analyzed in transwell motility assays. The percentage of cells positive for p75NTR in the original population was determined by immunostaining and compared to the percentage of p75NTR-positive cells in the migratory population (i.e., those cells that migrated to the underside of the transwell chamber during the assay). As a positive control for this assay, a mixture of 25% U87p75 cells and 75% U87pcDNA cells were used as input. At completion of the control assay, the migratory population contained approximately 50% p75NTR-positive cells (Figure 6C), as expected from initial experiments that demonstrated that p75NTR-positive cells migrate at a greater rate than the p75NTR-negative cells (Figure 3E and 3F). Similar effects were observed with the glioma patient specimens. The percentage of p75NTR-positive cells in the migratory population compared to the original population was increased by 40%–100% (Figure 6C), demonstrating that the p75NTR-positive cells within the glioma patient samples are more migratory than the p75NTR-negative glioma cells.
(A) Expression of p75NTR (brown) was examined by immunohistochemistry in normal human brain specimens (zero of five) and GBM patient specimens (17 of 20). Representative samples are shown. Slides were counterstained with hematoxylin (blue). Scale bars from top to bottom represent 100 μm, 50 μm, and 25 μm.
(B) p75NTR mRNA and protein were assessed in glioblastoma patient specimens (GBM) and normal human brain (N). Human dorsal root ganglia (DRG) were used as a positive control. GAPDH was used as an internal loading control for RT-PCR. β-Tubulin was used as a protein loading control. Neuronal (neurofilament 70: [NF70]) and glial (glial fibrillary acid protein [GFAP]) markers in patient specimens are shown.
(C) p75NTR-positive glioma cells from patient specimens have an increased migratory ability. Migration of in vitro–cultured glioma patient specimens was evaluated using transwell motility assays. As a positive control for the assay, a mixture of 25% U87p75 cells and 75% U87pcDNA cells were analyzed at the same time as the patient samples. For both the control sample and the patient samples, the percentage of p75NTR-positive cells in the migratory population (cells that migrated to the underside of the transwell) was increased compared to the percentage of p75NTR-positive cells in the original population. Values shown are the mean ± SEM. A single asterisk (*) indicates p < 0.05; double asterisks (**) indicate p < 0.01; and triple asterisks (***) indicate p < 0.001 (t-test within a given sample).
p75NTR Expression Results in Cytoskeletal Rearrangement and Changes in RhoA Activity
During the in vitro growth stage of the serial in vivo–selection procedure, we observed that the invasive glioma cells had striking morphological differences to the “tumor” cells. To examine the morphology of these cells, fluorescent staining of the actin cytoskeleton was performed. Staining of the actin cytoskeleton using rhodamine phalloidin revealed cells with numerous filamentous protrusions present only in the invading population (Figure 7A). Similarly, we found that expression of p75NTR alone induced structural rearrangement of the actin cytoskeleton similar to that of the in vivo–selected invasive cells (Figure 7B). Because the small molecular weight GTPase RhoA is a potential downstream readout from p75NTR that may help contribute to the distinct phenotype, we examined the effect of RhoA. Expression studies in HEK293 cells demonstrated that in the absence of ligand, p75NTR constitutively activated Rho, whereas ligand binding leads to a decrease in the levels of active Rho . In addition, Gehler et al.  have shown that neurotrophin-bound p75NTR induces growth cone filopodia through the modulation of RhoA and that neurotrophin binding is necessary and sufficient to regulate filopodia dynamics. We found that concomitant with the changes in actin cytoskeleton, cells expressing p75NTR had reduced RhoA activity (Figure 7C and 7D).
(A) Actin staining of tumor (left) and invasive cells (right) shows striking cytoskeletal rearrangement in the invading glioma cells. Actin cytoskeleton was visualized by staining fixed and permeabilized cells with rhodamine phalloidin (red), and cell nuclei were visualized with DAPI (blue). Numerous filamentous protrusions are seen in the invading glioma cells.
(B) p75NTR is sufficient to induce cytoskeletal rearrangement of glioma cells. U87pcDNA (left) and U87p75 (right) cells were fixed, permeabilized, and stained with rhodamine phalloidin (red) and DAPI to visualize the nucleus (blue).
(C) p75NTR expression results in decreased RhoA activity. RhoA activity was determined in U87pcDNA (pcDNA) and U87p75 (p75NTR) by RhoA pulldown assay using a GST fusion protein containing RBD-rhotekin that binds only to activated (GTP-bound) RhoA. Western blots using total cell lysates were performed for p75NTR, RhoA, and β-actin (used as a protein loading control).
(D) Bar graph shows quantitation of activated RhoA (Rho-GTP) as compared to total RhoA in both U87pcDNA and U87p75. Values shown are the mean ± SEM from four independent experiments.
Human malignant gliomas are highly invasive tumors. This highly invasive nature associates theses tumors with an extremely poor prognosis owing to recurrence of the tumor outside the margin of therapeutic resection . Invasion of glioma cells into the normal surrounding brain requires changes that make these cells distinct from their noninvasive counterparts. Specifically, these glioma cells activate a number of coordinate cellular programs that involve the regulation of many molecules, including adhesion molecules, extracellular matrix constituents, proteases, cytoskeleton components, and signaling molecules. Altered regulation of any of these constituents may lead to changes in glioma cell migration and invasion. Although numerous molecules have been implicated in the migration and invasion of gliomas, what triggers glioma cells to leave the main tumor mass and invade into the normal brain is not well understood. To this end, we have developed a serial in vivo–selection paradigm to isolate highly invasive glioma cells from a human glioma cell line that is noninvasive in xenotransplantation models. A similar approach has been used to successfully assess the global gene expression profile of both melanoma and breast cancer metastasis [7,8]. Using this strategy, we identified and verified genes that were up-regulated in the invading glioma cells. One of the most differentially expressed genes encodes the neurotrophin receptor p75NTR that is the focus of this study. We provide the first evidence both in vitro and in vivo that p75NTR is a major mediator of glioma migration and invasion.
In recent years, there has been a growing importance of the neurotrophin signaling axis in cancer. Specifically, there is increasing evidence that the neurotrophic receptor tyrosine kinase TrkB, sometimes in conjunction with its primary ligand BDNF, is over-expressed in a variety of human cancers, ranging from neuroblastomas to pancreatic ductal adenocarcinomas [51–55]. Here, we present data that the pan-neurotrophin receptor p75NTR is expressed in malignant glioma and is a major contributor to their highly invasive nature. Although a universal role for p75NTR in cancer has not been established, recent studies implicate p75NTR in the metastatic progression of melanoma, and specifically in those tumors that metastasize to the brain [43,46,56]. Conversely, p75NTR expression has been linked to the progression of prostate cancer, but in this cancer, p75NTR, which is expressed in normal prostate epithelia, is lost upon transformation . The divergence observed in the tumor progression of these two distinct tumors can likely be explained by the presence of Trk. In prostrate tumor cells, Trk expression is retained and mediates proliferation [42,57], whereas p75NTR-induced invasion in melanoma is independent of Trk expression . Thus the recurring theme emerges that p75NTR function is cell-type specific (even in cancer) and must be independently determined for each cellular context. Here, we have shown that p75NTR-induced glioma invasion is also Trk independent with neither mRNA nor protein for the Trk receptors expressed by the invading glioma cells. Further supporting the Trk independence of p75NTR-mediated glioma invasion is the finding that treatment of the invasive cells with cleavage-resistant pro-NGF (which cannot bind Trk; Figure S2) also enhanced the migration of invading glioma cells.
Tumor cells can survive by means of an autostimulatory (autocrine) signaling loop, such as that mediated by TrkB and BDNF, or through a paracrine cross-communication with their environment. In brain metastatic melanoma, normal brain tissue adjacent to the melanoma displays increased neurotrophin expression , making it tempting to speculate that the metastatic melanoma uses the neurotrophin-rich nervous system as a paracrine mediator of invasion. It has similarly not escaped our attention that the neurotrophin environment of the brain may provide an extremely advantageous milieu for an invading glioma cell. Our data show that the p75NTR-expressing glioma cells are ligand responsive and may therefore use neurotrophins available in the brain environment to their advantage. In addition, we show that the invasive nature of glioma cells expressing p75NTR is negated when these cells express mutant p75NTR receptors that no longer bind to neurotrophin.
The concept of p75NTR playing a role in migration is not unprecedented. Neural crest cells, the most extensively studied population of migrating cells in the nervous system, express p75NTR even before they commit to any cell differentiation lineage . In addition, Anton et al.  showed that stimulation of the p75NTR by NGF allowed Schwann cells to migrate on peripheral nerves, and examination of p75−/− mice showed severe impairment of Schwann cell migration, with no response to NGF . More recently, the Hempstead laboratory  has shown that activation of p75NTR with NGF or pro-NGF (the unprocessed, precursor form of NGF) caused migration of melanoma cells and increased expression of p75NTR correlated with advanced stages and invasive potential of melanoma brain metastasis . At present, the underlying mechanism of p75-induced migration of melanoma cells is not understood; however, p75NTR has been shown to interact with the actin cytoskeleton . The small GTPase RhoA is a downstream effector of p75NTR [27,28]. The capability of p75NTR to modulate the activity of RhoA provides a reasonable explanation as to how p75NTR regulation might result in changes in cellular architecture of glioma cells. We found that concomitant with increased glioma invasion, glioma cells expressing p75NTR showed reduced RhoA activity and striking actin rearrangement.
Previous molecular characterization has defined genetic changes between low-grade and high-grade glioma [61–67]. In addition, molecular signatures of glioblastoma subtypes have been identified, including profiles of primary and secondary glioblastoma subgroups [68–70]. On the other hand, very little is known with respect to the transcriptional profiles of invading glioma cells. Studies have been performed using laser capture microdissection in patient specimens to collect the invasive cells and the cells from the main tumor mass. Although this approach has been used successfully to identify invasion-related genes , these experiments make the assumption that the invasive cells at the leading edge of the tumor have distinct profiles from the main tumor mass and that only tumor cells at the invading edge express genes important for migration and invasion. Yet, within the highly heterogeneous environment of a glioblastoma, in which there are many hypoxic and necrotic regions, it would be easy to envision that tumor cells experiencing oxidative stress would activate mechanisms enabling them to move to a more favorable environment. As such, some genes may not be identified using such an approach. Indeed, our data show that in addition to p75NTR-expressing glioma cells at the invasive edge of patient tumors, histological analysis identified p75NTR-positive glioma cells in regions of the tumor not adjacent to normal brain parenchyma. An alternative explanation for the appearance of p75NTR-positive glioma cells is that p75NTR promotes survival of glioma cells in vivo, though we did not find that p75NTR conferred a survival advantage in vitro. Additionally, reports of “stem-like” cells in brain tumors suggest that brain tumors arise from the transformation of neural stem cells [71–73], and when implanted into the brains of SCID mice, these cells form highly invasive tumors [16,74,75]. Whether these brain tumor stem cells express p75NTR is an important question for future studies, especially given that nestin-positive, p75NTR-positive cells have been identified in the subventricular zone of the adult brain .
Identification of key regulatory proteins of glioma invasion is extremely important clinically because this will be used to provide therapeutically relevant targets to prevent malignant glioma recurrence at the invasive margin of gliomas . Herein, we present the first evidence that p75NTR is important in glioma migration, and the mere expression of p75NTR is sufficient to impart a dramatic invasive behavior on genetically distinct glioblastomas. Because p75NTR has also been implicated in the progression of melanoma, and specifically in those tumors that metastasize to the brain [33,46,77], therapies that target p75NTR, p75NTR downstream effectors, or their ligands may not only be beneficial for malignant glioma, but may target other metastatic diseases.
Materials and Methods
The human glioma cell line U87 was obtained from the American Type Culture Collection (http://www.atcc.org). The human glioma cell lines U251N and SF767 were kind gifts from V. W. Yong (University of Calgary, Calgary, Alberta, Canada) and M. Berens (Barrow Neurological Institute, Phoenix, Arizona, United States), respectively. All cells were maintained in complete medium (Dulbecco's Modified Eagle's Medium [DMEM] F12 supplemented with 10% heat-inactivated fetal bovine serum, 1% antibiotic/antimycotic, 0.1 mM nonessential amino acids, 2 mM L-glutamine and 1 mM sodium pyruvate (GIBCO BRL, http://www.invitrogen.com)] at 37 °C in a humidified 5% CO2 incubator. Cells were passaged by harvesting with trypsin when they reached 80%–90% confluence. Stable transfectants of U87 and SF767 cells were maintained in the same medium, with the addition of 400 μg/ml G418 or 200 μg/ml hygromycin, respectively (Invitrogen, http://www.invitrogen.com).
Generation of plasmids.
The GFP expression vector was pGFP-N1 from Clontech (http://www.clontech.com). The human p75NTR expression vector was constructed as described previously . The expression plasmids containing the p75NTR mutants were constructed either by subcloning of PCR fragments containing the desired p75NTR sequences (for p75CRD130 construct) or by PCR-based site-directed mutagenesis (for the p75CRD105 constructs). Primers used for the construction of the mutants were: p75CRD105 primers (sense: 5′-CGG GCT CGG GCC GCT CGA GCG GCC TCG TGT TC–3′; antisense: 5′-GAA CAC GAG GCC GCT CGA GCG GCC CGA GCC CG–3′) and template p75WT ; p75CRD130 primers (sense: 5′-GAA GAT CTC CAA GGA GGC ATG CCC CAC AGG CC–3′; antisense: 5′-CTC ACT ATA GGT CGA CCG GAA TTC G– 3′) and template pT3/T7-p75. The original templates were from B. Hempstead (p75WT; Cornell University Medical College) and M. Chao (pT3/T7-p75; New York University School of Medicine, New York, New York, United States). The sequences of all the mutant expression plasmids were confirmed prior to stable transfection. The p75NTR-specific siRNA expression vector was constructed by ligating a double-stranded hairpin oligonucleotide: 5′-GAT CCG AGG ATC GGA GGC TTG TCA TTC AAG AGA TGA CAA GCC TCC GAT CCT CTT TTT TGG AAA-3′, containing a p75NTR-specific siRNA sequence (underlined), into the pSilencer 2.1-U6 hygro vector (Ambion, http://www.ambion.com). The negative control pSilencer vector, containing a random siRNA with limited homology to any known human, mouse, or rat sequences, was obtained from Ambion.
Transfection of glioma cell lines.
Cells to be transfected were seeded at 2 × 105 cells/well of a six-well plate and incubated at 37 °C overnight in complete media. Vector DNA was introduced to the cells using FuGENE 6 transfection reagent (Roche Diagnostic, http://www.roche.com) according to the manufacturer's instructions. The cells were then incubated at 37 °C overnight; and the following day, the medium was changed to fresh complete medium containing an antibiotic (concentration determined by toxicity curve for cell line) to select for those cells that had taken up the vector. The cells were then grown under antibiotic selection until the wells were confluent. For GFP transfection, transfected cells were identified by fluorescent microscopy and GFP expression of greater than 95% was obtained by fluorescence-activated cell sorting. For p75NTR, p75CRD105, p75CRD130, and p75NTR-siRNA transfection, transfected cells were identified by RT-PCR and Western blot.
Six- to 8-wk-old female SCID mice were purchased from Charles River Laboratories (http://www.criver.com). The animals were housed in groups of three to five, maintained on a 12-h light/dark schedule with a temperature of 22 °C ± 1 °C and a relative humidity of 50% ± 5%. Food and water were available ad libitum. All procedures were reviewed and approved by the University of Calgary Animal Care Committee.
In vivo selection of invasive glioma cells.
Actively growing U87 cells expressing GFP and neomycin resistance genes (U87GFP) were harvested by trypsinization, washed, and resuspended in sterile PBS (137 mM NaCl, 8.1 mM Na2HPO4, 2.68 mM KCl, and 1.47 mM KH2PO4 [pH 7.5]). These cells were implanted intracerebrally into the right putamen of SCID mice (1 × 105 cells/mouse) at a depth of 3 mm through a scalp incision and a 0.5-mm burr hole made 1.5–2 mm right of the midline and 0.5–1 mm posterior to the coronal suture. Stereotactic techniques were described previously . Tumor formation was allowed to proceed for 21+ days, depending on the health of the mouse and the type of cells injected. The mice were then sacrificed and the brain examined using fluorescence. The brain was divided in half coronally; one half was used for frozen sections and the other used for tissue culture. For tissue culture, the hemisphere containing the main tumor mass was separated from the contralateral hemisphere, and the two pieces were treated individually. The tissue was minced into small pieces and dissociated with trypsin and DNase I at 37 °C. The tissue suspension was then forced through a 100-μm mesh, and the resulting cell suspension was centrifuged and resuspended in complete medium containing 400 μg/ml G418 to select for the GFP-transfected tumor cells. Cells obtained from the tumor mass were labeled as “tumor” cells, and those from the contralateral hemisphere were labeled as “invasive” cells. Tumor and invasive cells were then reinoculated into SCID mice, and the procedure was repeated.
Total cellular RNA was extracted from subconfluent cells using Trizol Reagent (Invitrogen) and DNase-treated using DNA-free (Ambion). The reverse transcription reaction took place in a buffer of 10 mM Tris-HCl (pH 9.0), 50 mM KCl, and 1.5 mM MgCl2, and contained 3 μg of total RNA, 25 units of RNAguard RNase inhibitor, 1 mM each of deoxynucleoside triphosphates, 100 ng of pd(N)6 random hexanucleotide primers (Amersham Biosciences, http://www.amersham.com), and 200 units of Superscript II reverse transcriptase (Invitrogen). The PCR amplification reaction was carried out in the same buffer and contained 1 μl of the cDNA synthesis reaction, 80 μM each of deoxynucleoside triphosphates, 1 unit of Taq DNA polymerase (Amersham Biosciences), and 0.1 μM each of p75NTR-specific primers (forward: 5′-CGT ATT CCG ACG AGG CCA ACC-3′; reverse: 5′-CCA CAA GGC CCA CAA CCA CAG C-3′), p75CRD105-specific primers (forward: 5′-CGG GCT CGG GCC GCT CGA GCG GCC TCG TGT TC-3′; reverse primer: 5′-GAA CAC GAG GCC GCT CGA GCG GCC CGA GCC CG-3′), p75CRD130-specific primers (forward: 5′-GAA GAT CTC CAA GGA GGC ATG CCC CAC AGG CC-3′; reverse primer: 5′-CTC ACT ATA GGT CGA CCG GAA TTC G-3′), or 0.2 μM each of GAPDH-specific primers (forward primer: 5′-CGG AGT CAA CGG ATT TGG TCG TAT-3′; reverse primer: 5′-AGC CTT CTC CAT GGT GGT GAA GAC-3′). The amplification consisted of 35 cycles of 45 s at 94 °C, 30 s at 63 °C, and 45 s at 72 °C, followed by a 7-min extension at 72 °C after the last cycle. The reaction products were then resolved on a 1% agarose gel containing ethidium bromide.
Total cellular lysates were obtained by gentle rocking in lysis buffer (20 mM Tris [pH 8.0], 137.5 mM NaCl, 10% glycerol, 1% Nonidet P-40, 25 μg/ml aprotinin, 10 μg/ml leupeptin, 3 mM sodium orthovanadate, 1 mM PMSF) at 4 °C. Protein extracts of human glioma biopsies were obtained by immersing the samples in ice-cold extraction buffer (50 mM Tris [pH 7.6], 200 mM NaCl, 10 mM CaCl2, 1% Triton X-100) followed by homogenization on ice. Cellular debris was removed by centrifugation, and protein quantification was performed using the bicinchoninic acid (BCA) assay (Pierce Biotechnology, http://www.piercenet.com). Proteins were resolved on 10% SDS-PAGE gels, and Western blots were performed using the following primary antibodies: rabbit polyclonal anti-human p75NTR (Promega, http://www.promega.com), goat polyclonal anti-pyruvate kinase (Chemicon, http://www.chemicon.com), mouse monoclonal anti-neurofilament, 70 kDa (Chemicon), mouse monoclonal anti-glial fibrillary acid protein (ChemiconA), or mouse monoclonal anti-β-tubulin (Sigma-Aldrich, http://www.sigmaaldrich.com). The appropriate HRP-conjugated secondary antibody (Pierce Biotechnology) was used and visualized using enhanced chemiluminescence (Amersham Biosciences).
Flow cytometric analysis of p75NTR expression.
Cells were collected using Puck's EDTA at 37 °C and then washed in PBS containing 1 mM EDTA (PBS/EDTA). Cells were then treated with monoclonal anti-p75NTR, clone ME20.4 (which recognizes the extracellular domain; Upstate Biotechnology, http://www.upstate.com), diluted 1:250 in PBS/EDTA for 30 min on ice. The negative control sample was incubated in only PBS/EDTA. After washing with PBS/EDTA, cells were treated with Alexa 488–conjugated goat anti-mouse IgG (Invitrogen Molecular Probes, http://probes.invitrogen.com) diluted 1:500 in PBS/EDTA for 30 min on ice. Cells were then washed with PBS/EDTA, resuspended in PBS/EDTA, and analyzed on a FACScan flow cytometer (Becton, Dickinson and Company, http://www.bdbiosciences.com).
Enzyme-linked immunosorbent assay.
Cells were allowed to condition the medium for 5 d. The conditioned medium was then collected, centrifuged, and filtered through a 0.2-μm syringe filter (VWR International, http://www.vwr.com). The remaining cells were washed with ice-cold PBS, and total cellular lysates were extracted as described for Western blot. Protein quantification was performed using the BCA assay (Pierce Biotechnology) and BDNF enzyme-linked immunosorbent assays (ELISAs) (R&D Systems, http://www.rndsystems.com) were performed as per the company protocol. Briefly, MaxiSorp ELISA plates (Nalge Nunc International, http://www.nalgenunc.com) were coated with monoclonal anti-human BDNF (R&D Systems), nonspecific binding was blocked, and serial dilutions of recombinant human BDNF (Sigma-Aldrich), equal volumes of conditioned medium, or equal quantities of lysate were added. Bound antigen was detected using the corresponding biotinylated antibody, streptavidin HRP, and a tetramethylbenzidine substrate (R&D Systems).
Circular monolayer migration assay.
Migration assays were performed using a microliter-scale radial monolayer migration assay as described by Berens et al. . Briefly, ten-well Teflon-masked microscope slides were coated with 20 μg/ml laminin. Cells were seeded through a cell sedimentation manifold (Creative Scientific Methods, http://www.cre8ive-sci.com) at 2,000 cells/well to establish a circular 1-mm diameter confluent monolayer. Once the sedimentation manifolds were removed, cells were given complete medium containing the appropriate treatment. A digital image of the cells was taken (before migration = 0 h) using a Zeiss Axiovert 200M inverted fluorescent microscope (Carl Zeiss, http://www.zeiss.com). The cells were then incubated in a humidified chamber at 37 °C and 5% CO2, and a second digital image was taken 48 h later. Best-fit circles were drawn around the area covered by the cells at the 0-h and 48-h time points and the actual cell area determined using Axiovision 4.2 imaging software (Carl Zeiss). Quantitative migration scores were calculated as the increase in the area covered by the cells beyond the initial area of the cells.
In vitro invasion assay.
Matrigel (BD Bioscience, Mississauga, Ontario, Canada) was diluted with two parts of cold serum-free medium, layered onto an 8-μm pore-size transwell chamber (BD Bioscience, http://www.bdbiosciences.com), and incubated at room temperature for 1 h. The wells were then rinsed with serum-free medium. The coated chambers were placed into the wells of a 24-well tissue culture plate containing 500 μl of media with or without the desired treatment. Serum-starved cells (2.5 × 104) were seeded into each chamber, in a volume of 500 μl of the same medium contained in the bottom of the well, and incubated at 37 °C for 48 h. The medium was then removed from the chambers and cells scraped off the top of the membrane using a PBS-soaked cotton-tipped swab. Cells were fixed to the bottom of the chamber with methanol, stained in hematoxylin, and mounted on slides. Invasion was quantified by counting the stained cells adherent to the lower side of the membranes in ten fields (at 10× magnification) for each of three chambers for each condition.
In vivo studies of p75NTR overexpression in an intracranial glioma model.
Actively growing U87pcDNA, U87p75, U87CRD105, U87CRD130, U251NpcDNA, and U251Np75 cells were implanted intracerebrally into SCID mice as described previously . Mice were sacrificed weekly from day 14–42. At each time point, the brains were removed, frozen in OCT compound (Tissue-Tek; Electron Microscopy Sciences, http://www.emsdiasum.com), and cryosectioned for examination by immunohistochemistry.
Frozen sections were air dried at room temperature, fixed with cold acetone, and then rinsed with PBS. Paraffin sections were dewaxed and rehydrated using a xylene/ethanol series followed by rinsing with PBS. Endogenous peroxidases in the sections were inactivated with 0.075% H2O2/methanol, and nonspecific binding was blocked with 10% normal goat serum in PBS. The sections were then incubated with rabbit polyclonal anti-human p75NTR (Promega, http://www.promega.com) or mouse monoclonal anti-human nuclei (Chemicon) in blocking buffer overnight at 4 °C. Following washing with PBS, the appropriate biotinylated secondary antibody (Vector Laboratories, http://www.vectorlabs.com) was applied. Avidin-biotin peroxidase complexes were then formed using the VECTASTAIN Elite ABC kit (Vector Laboratories) and detected by addition of SIGMAFAST DAB (3,3′-diaminobenzidine tetrahydrochloride) (Sigma-Aldrich). The SIGMAFAST DAB was converted to a brown reaction product by the peroxidase. Hematoxylin (for paraffin sections) and toluidine blue (for frozen sections) were used as nuclear counterstains. Sections were then dehydrated in an ethanol/xylene series and mounted with Entellan (Electron Microscopy Sciences).
Coverslips were coated with a Collagen I (3 mg/ml; Vitrogen 100; Cohesion Technologies, http://www.cohesiontech.com) and incubated overnight at 37 °C. Excess collagen solution was aspirated, and cells were plated at 2 × 105/mL in DMEM culture medium (DMEM with 10% FBS, 6 mM L-glutamine, 100 μM nonessential amino acids, 1 mM sodium pyruvate, 400 μg/ml G418) and allowed to equilibrate overnight at 37 °C, 5% CO2. Coverslips were then rinsed twice with PBS, fixed in 3.7% formaldehyde diluted in PBS for 10 min, and rinsed twice with PBS. Unpolymerized actin was extracted for 3 min in CSK buffer (10 mM MES [pH 6.1], 138 mM KCl, 3 mM MgCl2, 2 mM EGTA, 320 mM sucrose, 0.1% Triton X-100) followed by two rinses with PBS. Alexa Fluor 568 phalloidin (Invitrogen) was diluted 1:40 in 1% BSA/PBS and 200 μl of this solution was added to each coverslip for 20 min at room temperature. Coverslips were rinsed twice with PBS, counterstained with a 500 nM solution of DAPI for 3 min, mounted in glycerol, and imaged with an Olympus IX70 Delta Vision RT Microscope (http://www.olympus.co.jp/en/) and the SoftWoRx software package.
Tumor and normal tissues were obtained from the Canadian Brain Tumor Tissue Bank in London, Ontario, and Foothills Hospital, Calgary, Alberta. Briefly, tissue was taken during surgery while patients were under a general anesthetic, and was placed immediately in liquid nitrogen and stored at −80 °C or placed in culture medium for establishment of short-term cultures. An institutional ethics board approved the collection and use of all of the surgical tissue used, and all of the patients gave signed informed consent. The following tissues were studied: 20 GBMs, eight anaplastic astrocytomas, one anaplastic oligodendroglioma, five astrocytomas, five mixed oligoastrocytomas, one oligodendroglioma, and five controls obtained during nontumor brain surgery.
Short-term culture of primary human glioma cells.
Operative samples of human gliomas were obtained during brain tumor surgery and transported to the laboratory in culture medium. Short-term cultures were then established. Briefly, necrotic and connective tissue and any blood clots were removed using forceps, and the remaining tissue was washed in PBS and cut into pieces of approximately 1 mm2. The tissue was then incubated for 30 min at 37 °C in an enzyme cocktail of trypsin (0.25%) and DNase I (10 μg/ml) in PBS. The digested tissue was strained through a 100-μm mesh and washed with PBS. The cells were then pelleted and washed with DMEM-F12 media. Following lysis of red blood cells, the remaining cells were washed with PBS, pelleted, resuspended in complete media containing 20% FBS, and plated.
Transwell motility assay of primary human glioma cells.
Primary human glioma cells cultured for less than 3 wk were “serum-starved” by incubating them in medium containing only 1% FBS for 2 h at 37 °C and 5% CO2. Cells were then released from the culture dish using Puck's EDTA (1 mM EDTA, 10 mM HEPES, 5 mM KCl, 140 mM NaCl, 4 mM NaHCO3, and 6 mM dextrose [pH 7.3]) at 37 °C. Cells (2.5 × 104) suspended in 1% FBS medium were plated in eight-well chamber slides (Nunc) and transwell chambers (Costar) coated with 20 μg/ml laminin. Medium containing 1% FBS was placed below the chamber. The cells were incubated at 37 °C and 5% CO2 for 6 h. The medium was then removed from the chambers, and cells were fixed with 4% paraformaldehyde. The cells were then stained for human p75NTR, as described for immunohistochemical staining, and counterstained with hematoxylin. In the transwell chamber, cells that did not migrate were scraped off the top of the membrane using a cotton-tipped swab. Migration was quantified by counting the p75NTR-positive (brown) and p75NTR-negative (blue) cells in the original population (on the slide) or in the migratory population (adherent to the under side of the transwell membrane) in five fields (at 20× magnification) for each of four chambers.
Figure S1. In Vivo–Selected U251 Invasive Cells Express p75NTR
U251 human glioma GFP-expressing cell line was implanted into the brains of SCID mice; and 4–6 wk later, the mice were sacrificed. The ipsilateral side of the brain (containing a grossly visible tumor) was separated from the contralateral side (containing only isolated invasive glioma cells) and both were grown in culture. These noninvasive (tumor [U251T]) and highly invasive (invasive [U251R]) cells were reimplanted and the process repeated to select for increasingly noninvasive or invasive glioma cells. Through the serial in vivo selection, highly invasive U251 glioma cells were isolated. Western-blot analysis of p75NTR expression in tumor and invasive U251 human glioma cells shows a dramatic increase in endogenous p75NTR expression in the U251 invasive cells as compared to the U251 tumor cells. U87 tumor (U87T) and invasive (U87R) cells were used for comparison (A). The invasive U251 cells, which endogenously express p75NTR, showed a significant increase in migration (B) and invasion (C) compared to U251 tumor cells. Double asterisks(∗∗) indicate p < 0.001 (tumor vs. invasive, paired t-test). Values shown are the mean ± standard error of the mean (SEM) from three independent experiments.
(136 KB TIF)
Figure S2. Invasive Glioma Cells Expressing p75NTR Increase Migration in Response to Cleavage-Resistant Form of pro-NGF
Treatment of invasive cells with a cleavage-resistant form of pro-NGF significantly increased migration at concentrations as low as 1 ng/ml. Values shown are the mean ± SEM for a single experiment. Similar results were seen in three independent experiments Double asterisks (**) indicate p < 0.01, and triple asterisks (***) indicate p < 0.001 versus control (one-way analysis of variance [ANOVA] with Bonferroni post-test). Statistics were done on the experiment shown.
(58 KB TIF)
Figure S3. Autocrine BDNF Is Bound to the Cell Surface of p75NTR-Expressing U87 Cells
BDNF expression was confirmed by RT-PCR (A). The amount of BDNF protein contained in the conditioned medium (B) or cell associated before and after treatment with a cell surface-stripping reagent (C) was measured by ELISA in cells expressing either empty vector (pcDNA) or a p75NTR-expression vector (p75), U87 pcDNA and U87p75. Values shown are the mean ± SEM from a single experiment; triple asterisks (***) indicate p < 0.001 U87p75 compared to pcDNA; triple pluses (+++) indicate p < 0.001 U87p75 before and after cell surface stripping. Similar results were seen in three independent experiments.
(153 KB TIF)
Figure S4. Down-Regulation of p75NTR Expression Using RNAi Decreases Migration and Invasion of In Vivo–Selected U87 Invasive Glioma Cells
(A) RT-PCR (GAPDH used as a loading control) and (B) Western blot (pyruvate kinase used as a loading control) confirm down-regulation of p75NTR in the in vivo–selected invasive glioma cells, transiently transfected with a p75NTR-specific siRNA. (C) Down-regulation of p75NTR levels by siRNA in the in vivo–selected invasive glioma cells significantly reduces their circular migration and transwell invasion. Values shown are the mean ± SEM from four independent experiments. Double asterisks (**) indicate p < 0.01 versus random siRNA transfected cells (paired t-test).
(136 KB TIF)
Figure S5. U87p75 Glioma Cells Are Found Substantial Distances from the Main Tumor Mass
To further illustrate the invasive nature of the p75NTR-expressing glioma cells, serial sections of brains from animals implanted with either pcDNA or p75NTR-expressing U87 glioma cells were stained using a human nuclear-specific antibody. U87p75 glioma cells were found substantial distances from the main tumor mass; right panel shows whole-brain sections posterior to the main tumor. (First two panels are the same as Figure 4).
(1.1 MB TIF)
We thank Z. Q. Shi, H. Muzik, M. Slovack, and B. Sun at the University of Calgary for their technical support and expertise. ALMJ was supported by the Alberta Heritage Foundation for Medical Research (AHFMR), Canadian Institute of Health Research, and Natural Sciences and Engineering Research Council studentships. JJR was supported by a postdoctoral fellowship from the Alberta Cancer Board. IFP is an AHFMR Clinician Scientist. SMR is a scientist for the AHFMR and holds a Canada Research Chair in Cancer Biology. AL and LW were supported by postdoctoral fellowships from the AHFMR. PAF and DLS share senior authorship of this paper.
SMR, PAF, and DLS conceived and designed the experiments. ALMJ, XL, JJR, AL, and LW performed the experiments. ALMJ, XL, JJR, AL, LW, SMR, PAF, and DLS analyzed the data. MGH, IFP, BLH, and SMR contributed reagents/materials/analysis tools. ALMJ and DLS wrote the paper. MGH and IFP supplied clinical surgical tissue for investigation.
- 1. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, et al. (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46: 183–188.
- 2. Senger D, Cairncross JG, Forsyth PA (2003) Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype? Cancer J 9: 214–221.
- 3. Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39: 235–250.
- 4. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624–1636.
- 5. Demuth T, Berens ME (2004) Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70: 217–228.
- 6. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, et al. (2003) Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116: 4409–4417.
- 7. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, et al. (2001) Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: A cDNA microarray analysis. J Neurooncol 53: 161–176.
- 8. Holtkamp N, Afanasieva A, Elstner A, van Landeghem FK, Konneker M, et al. (2005) Brain slice invasion model reveals genes differentially regulated in glioma invasion. Biochem Biophys Res Commun 336: 1227–1233.
- 9. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, et al. (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7: 7–16.
- 10. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, et al. (2001) Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 7: 2480–2489.
- 11. Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, et al. (2001) Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res 61: 4190–4196.
- 12. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532–535.
- 13. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518–524.
- 14. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H (1990) Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: Developmental and topographical expression in the brain. Proc Natl Acad Sci U S A 87: 5454–5458.
- 15. Hallbook F, Ibanez CF, Persson H (1991) Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 6: 845–858.
- 16. Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294: 1945–1948.
- 17. Rodriguez-Tebar A, Dechant G, Barde YA (1990) Binding of brain-derived neurotrophic factor to the nerve growth factor receptor. Neuron 4: 487–492.
- 18. Rodriguez-Tebar A, Dechant G, Gotz R, Barde YA (1992) Binding of neurotrophin-3 to its neuronal receptors and interactions with nerve growth factor and brain-derived neurotrophic factor. EMBO J 11: 917–922.
- 19. Chao MV (2003) Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci 4: 299–309.
- 20. Dechant G, Barde YA (2002) The neurotrophin receptor p75(NTR): Novel functions and implications for diseases of the nervous system. Nat Neurosci 5: 1131–1136.
- 21. Kaplan DR, Miller FD (2003) Axon growth inhibition: Signals from the p75 neurotrophin receptor. Nat Neurosci 6: 435–436.
- 22. Roux PP, Barker PA (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67: 203–233.
- 23. Hempstead BL (2002) The many faces of p75NTR. Curr Opin Neurobiol 12: 260–267.
- 24. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002) P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420: 74–78.
- 25. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, et al. (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427: 843–848.
- 26. Bentley CA, Lee KF (2000) p75 is important for axon growth and Schwann cell migration during development. J Neurosci 20: 7706–7715.
- 27. Yamashita T, Tucker KL, Barde YA (1999) Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron 24: 585–593.
- 28. Yamashita T, Higuchi H, Tohyama M (2002) The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J Cell Biol 157: 565–570.
- 29. DeFreitas MF, McQuillen PS, Shatz CJ (2001) A novel p75NTR signaling pathway promotes survival, not death, of immunopurified neocortical subplate neurons. J Neurosci 21: 5121–5129.
- 30. Bamji SX, Majdan M, Pozniak CD, Belliveau DJ, Aloyz R, et al. (1998) The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death. J Cell Biol 140: 911–923.
- 31. Troy CM, Friedman JE, Friedman WJ (2002) Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. J Biol Chem 277: 34295–34302.
- 32. Boyd JG, Gordon T (2001) The neurotrophin receptors, trkB and p75, differentially regulate motor axonal regeneration. J Neurobiol 49: 314–325.
- 33. Song XY, Zhong JH, Wang X, Zhou XF (2004) Suppression of p75NTR does not promote regeneration of injured spinal cord in mice. J Neurosci 24: 542–546.
- 34. Yamauchi J, Chan JR, Shooter EM (2004) Neurotrophins regulate Schwann cell migration by activating divergent signaling pathways dependent on Rho GTPases. Proc Natl Acad Sci U S A 101: 8774–8779.
- 35. Anton ES, Weskamp G, Reichardt LF, Matthew WD (1994) Nerve growth factor and its low-affinity receptor promote Schwann cell migration. Proc Natl Acad Sci U S A 91: 2795–2799.
- 36. Yamashita T, Tohyama M (2003) The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat Neurosci 6: 461–467.
- 37. Dubreuil CI, Winton MJ, McKerracher L (2003) Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 162: 233–243.
- 38. Niederost B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE (2002) Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J Neurosci 22: 10368–10376.
- 39. Weis C, Wiesenhofer B, Humpel C (2002) Nerve growth factor plays a divergent role in mediating growth of rat C6 glioma cells via binding to the p75 neurotrophin receptor. J Neurooncol 56: 59–67.
- 40. Bhakar AL, Howell JL, Paul CE, Salehi AH, Becker EB, et al. (2003) Apoptosis induced by p75NTR overexpression requires Jun kinase-dependent phosphorylation of Bad. J Neurosci 23: 11373–11381.
- 41. Tysnes BB, Mahesparan R (2001) Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 53: 129–147.
- 42. Djakiew D (2000) Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42: 150–160.
- 43. Herrmann JL, Menter DG, Hamada J, Marchetti D, Nakajima M, et al. (1993) Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: Melanoma p75 functions independently of trkA. Mol Biol Cell 4: 1205–1216.
- 44. Marchetti D, Menter D, Jin L, Nakajima M, Nicolson GL (1993) Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production. Int J Cancer 55: 692–699.
- 45. Perez M, Regan T, Pflug B, Lynch J, Djakiew D (1997) Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 30: 274–279.
- 46. Shonukan O, Bagayogo I, McCrea P, Chao M, Hempstead B (2003) Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene 22: 3616–3623.
- 47. Walch ET, Albino AP, Marchetti D (1999) Correlation of overexpression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Int J Cancer 82: 112–120.
- 48. Yan H, Chao MV (1991) Disruption of cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding. J Biol Chem 266: 12099–12104.
- 49. Gehler S, Gallo G, Veien E, Letourneau PC (2004) p75 neurotrophin receptor signaling regulates growth cone filopodial dynamics through modulating RhoA activity. J Neurosci 24: 4363–4372.
- 50. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, et al. (1996) Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56: 694–699.
- 51. Aoyama M, Asai K, Shishikura T, Kawamoto T, Miyachi T, et al. (2001) Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett 164: 51–60.
- 52. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, et al. (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
- 53. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, et al. (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034–1039.
- 54. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, et al. (2001) Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 19: 689–696.
- 55. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14: 759–767.
- 56. Menter DG, Herrmann JL, Marchetti D, Nicolson GL (1994) Involvement of neurotrophins and growth factors in brain metastasis formation. Invasion Metastasis 14: 372–384.
- 57. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D (1995) Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 136: 262–268.
- 58. Marchetti D, Parikh N, Sudol M, Gallick GE (1998) Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells. Oncogene 16: 3253–3260.
- 59. Stemple DL, Anderson DJ (1992) Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell 71: 973–985.
- 60. Walsh GS, Krol KM, Crutcher KA, Kawaja MD (1999) Enhanced neurotrophin-induced axon growth in myelinated portions of the CNS in mice lacking the p75 neurotrophin receptor. J Neurosci 19: 4155–4168.
- 61. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, et al. (2002) Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12: 108–116.
- 62. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, et al. (1999) Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling. Cancer Res 59: 4228–4232.
- 63. Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, et al. (2002) Identification of combination gene sets for glioma classification. Mol Cancer Ther 1: 1229–1236.
- 64. Ljubimova JY, Khazenzon NM, Chen Z, Neyman YI, Turner L, et al. (2001) Gene expression abnormalities in human glial tumors identified by gene array. Int J Oncol 18: 287–295.
- 65. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, et al. (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602–1607.
- 66. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, et al. (2001) Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61: 6885–6891.
- 67. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, et al. (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60: 6617–6622.
- 68. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814–5819.
- 69. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, et al. (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678–1686.
- 70. Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66: 159–167.
- 71. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, et al. (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193–206.
- 72. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, et al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100: 15178–15183.
- 73. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821–5828.
- 74. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396–401.
- 75. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011–7021.
- 76. Giuliani A, D'Intino G, Paradisi M, Giardino L, Calza L (2004) p75(NTR)-immunoreactivity in the subventricular zone of adult male rats: Expression by cycling cells. J Mol Histol 35: 749–758.
- 77. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, et al. (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903–912.
- 78. Berens ME, Rief MD, Loo MA, Giese A (1994) The role of extracellular matrix in human astrocytoma migration and proliferation studied in a microliter scale assay. Clin Exp Metastasis 12: 405–415.